[8-K] Atossa Therapeutics, Inc. Reports Material Event
Atossa Therapeutics, Inc. reported on August 12, 2025 that it issued a press release announcing financial results for the quarter ended June 30, 2025 and providing a company update. The press release is attached as Exhibit 99.1 and the filing includes a cover page Interactive Data File as Exhibit 104. The Company states the information in Items 2.02 and 9.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or subject to certain Securities Act liabilities. This Current Report is signed by Heather Rees, Chief Financial Officer. No numerical financial metrics are included in the 8-K text provided here; consult Exhibit 99.1 for the detailed results and commentary.
Atossa Therapeutics, Inc. ha comunicato il 12 agosto 2025 di aver pubblicato un comunicato stampa che annuncia i risultati finanziari del trimestre chiuso al 30 giugno 2025 e fornisce un aggiornamento aziendale. Il comunicato 猫 allegato come Exhibit 99.1 e la registrazione contiene un file dati interattivo di copertina come Exhibit 104. La Societ脿 dichiara che le informazioni contenute nelle Items 2.02 e 9.01, incluso l'Exhibit 99.1, non devono essere considerate "filed" ai fini della Sezione 18 dell'Exchange Act n茅 soggette ad alcune responsabilit脿 previste dallo Securities Act. Il presente Current Report 猫 firmato da Heather Rees, Chief Financial Officer. Nel testo dell'8-K qui riportato non sono inclusi indicatori finanziari numerici; consultare l'Exhibit 99.1 per i risultati dettagliati e i commenti.
Atossa Therapeutics, Inc. inform贸 el 12 de agosto de 2025 que emiti贸 un comunicado de prensa anunciando los resultados financieros del trimestre terminado el 30 de junio de 2025 y brindando una actualizaci贸n de la compa帽铆a. El comunicado se adjunta como Exhibit 99.1 y la presentaci贸n incluye un archivo de datos interactivo en la portada como Exhibit 104. La Compa帽铆a indica que la informaci贸n en los Items 2.02 y 9.01, incluido el Exhibit 99.1, no deber谩 considerarse "filed" a efectos de la Secci贸n 18 del Exchange Act ni sujeta a ciertas responsabilidades previstas por el Securities Act. Este Current Report est谩 firmado por Heather Rees, Chief Financial Officer. En el texto del 8-K aqu铆 no se incluyen m茅tricas financieras num茅ricas; consulte el Exhibit 99.1 para los resultados detallados y los comentarios.
Atossa Therapeutics, Inc.電� 2025雲� 8鞗� 12鞚� 鞛愲 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 瓴瓣臣毳� 氚滍憸頃橁碃 須岇偓 鞐呺嵃鞚错姼毳� 鞝滉车頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅�, 鞝滌稖靹滊鞐愲姅 響滌 鞚疙劙霝欗嫲敫� 雿办澊韯� 韺岇澕鞚� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� Items 2.02 氚� 9.01鞐� 韽暔霅� 鞝曤炒(Exhibit 99.1 韽暔)臧� Exchange Act 靹轨厴 18鞚� 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婌溂氅� 韸轨爼 Securities Act 毂呾瀯鞚� 雽�靸侅澊 霅橃 鞎婋姅雼り碃 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 氤� Current Report電� 斓滉碃鞛毂呾瀯鞛� Heather Rees鞚� 靹滊獏鞙茧 鞝滌稖霅橃棃鞀惦媹雼�. 鞐赴 鞝滉车霅� 8-K 氤鸽鞐愲姅 靾橃箻順� 鞛 歆�響滉皜 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿�, 靸侅劯頃� 瓴瓣臣鞕� 靹る獏鞚� Exhibit 99.1鞚� 彀胳“頃橃嫮鞁滌槫.
Atossa Therapeutics, Inc. a d茅clar茅 le 12 ao没t 2025 avoir publi茅 un communiqu茅 de presse annon莽ant les r茅sultats financiers du trimestre clos le 30 juin 2025 et fournissant une mise 脿 jour de la soci茅t茅. Le communiqu茅 est joint en tant que Exhibit 99.1 et le d茅p么t comprend un fichier de donn茅es interactif de la page de couverture en tant que Exhibit 104. La Soci茅t茅 indique que les informations figurant aux Items 2.02 et 9.01, y compris l'Exhibit 99.1, ne doivent pas 锚tre consid茅r茅es comme "filed" aux fins de la Section 18 du Exchange Act ni 锚tre soumises 脿 certaines responsabilit茅s pr茅vues par le Securities Act. Ce Current Report est sign茅 par Heather Rees, Chief Financial Officer. Aucune donn茅e financi猫re chiffr茅e ne figure dans le texte de l'8-K pr茅sent茅 ici ; veuillez consulter l'Exhibit 99.1 pour les r茅sultats d茅taill茅s et les commentaires.
Atossa Therapeutics, Inc. berichtete am 12. August 2025, dass eine Pressemitteilung ver枚ffentlicht wurde, die die Finanzergebnisse f眉r das am 30. Juni 2025 endende Quartal ank眉ndigt und ein Unternehmensupdate enth盲lt. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt und die Einreichung enth盲lt eine interaktive Datendatei der Titelseite als Exhibit 104. Das Unternehmen erkl盲rt, dass die Informationen in den Items 2.02 und 9.01, einschlie脽lich Exhibit 99.1, nicht als "filed" im Sinne von Abschnitt 18 des Exchange Act angesehen werden sollen und nicht bestimmten Haftungsbestimmungen des Securities Act unterliegen. Dieser Current Report ist von Heather Rees, Chief Financial Officer, unterzeichnet. Im hier ver枚ffentlichten 8-K-Text sind keine numerischen Finanzkennzahlen enthalten; f眉r detaillierte Ergebnisse und Erl盲uterungen konsultieren Sie bitte Exhibit 99.1.
- Timely disclosure: company publicly released a press release announcing financial results for the quarter ended June 30, 2025 and attached it as Exhibit 99.1 to the 8-K.
- Inclusion of an Interactive Data cover page (Exhibit 104) improves machine-readable accessibility of the filing.
- The 8-K text does not include any numerical financial metrics or operational details; investors must consult Exhibit 99.1 for substantive results.
- The Company states the press release shall not be deemed "filed" for Section 18 or certain Securities Act liabilities, which limits the exhibit's statutory filing protections.
Insights
TL;DR: Routine 8-K attaching a press release with Q2 2025 results; the filing itself contains no financial details, so immediate market impact is limited.
The report notifies investors that Atossa issued a press release for the quarter ended June 30, 2025 and attaches that release as Exhibit 99.1. Because the 8-K text does not include revenue, EPS, cash position, or guidance, the filing serves primarily as a pointer to the exhibit rather than a standalone disclosure of performance metrics. The company also uses standard language that the exhibit is not deemed "filed" for Section 18 purposes, which is common but reduces the filing's statutory liability profile. Investors should review Exhibit 99.1 for material numeric information.
TL;DR: Properly executed Form 8-K with required exhibits and officer signature; governance procedures appear followed, but substance is in the attached press release.
The document fulfills Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits) by attaching a press release and interactive data cover page. Signature by the CFO, Heather Rees, completes the required attestation for current reports. The filing's declaration that the press release is not "filed" for certain legal purposes is routine disclosure practice. Overall, the 8-K is procedurally sound but provides limited analytic content without Exhibit 99.1.
Atossa Therapeutics, Inc. ha comunicato il 12 agosto 2025 di aver pubblicato un comunicato stampa che annuncia i risultati finanziari del trimestre chiuso al 30 giugno 2025 e fornisce un aggiornamento aziendale. Il comunicato 猫 allegato come Exhibit 99.1 e la registrazione contiene un file dati interattivo di copertina come Exhibit 104. La Societ脿 dichiara che le informazioni contenute nelle Items 2.02 e 9.01, incluso l'Exhibit 99.1, non devono essere considerate "filed" ai fini della Sezione 18 dell'Exchange Act n茅 soggette ad alcune responsabilit脿 previste dallo Securities Act. Il presente Current Report 猫 firmato da Heather Rees, Chief Financial Officer. Nel testo dell'8-K qui riportato non sono inclusi indicatori finanziari numerici; consultare l'Exhibit 99.1 per i risultati dettagliati e i commenti.
Atossa Therapeutics, Inc. inform贸 el 12 de agosto de 2025 que emiti贸 un comunicado de prensa anunciando los resultados financieros del trimestre terminado el 30 de junio de 2025 y brindando una actualizaci贸n de la compa帽铆a. El comunicado se adjunta como Exhibit 99.1 y la presentaci贸n incluye un archivo de datos interactivo en la portada como Exhibit 104. La Compa帽铆a indica que la informaci贸n en los Items 2.02 y 9.01, incluido el Exhibit 99.1, no deber谩 considerarse "filed" a efectos de la Secci贸n 18 del Exchange Act ni sujeta a ciertas responsabilidades previstas por el Securities Act. Este Current Report est谩 firmado por Heather Rees, Chief Financial Officer. En el texto del 8-K aqu铆 no se incluyen m茅tricas financieras num茅ricas; consulte el Exhibit 99.1 para los resultados detallados y los comentarios.
Atossa Therapeutics, Inc.電� 2025雲� 8鞗� 12鞚� 鞛愲 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 瓴瓣臣毳� 氚滍憸頃橁碃 須岇偓 鞐呺嵃鞚错姼毳� 鞝滉车頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅�, 鞝滌稖靹滊鞐愲姅 響滌 鞚疙劙霝欗嫲敫� 雿办澊韯� 韺岇澕鞚� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� Items 2.02 氚� 9.01鞐� 韽暔霅� 鞝曤炒(Exhibit 99.1 韽暔)臧� Exchange Act 靹轨厴 18鞚� 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婌溂氅� 韸轨爼 Securities Act 毂呾瀯鞚� 雽�靸侅澊 霅橃 鞎婋姅雼り碃 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 氤� Current Report電� 斓滉碃鞛毂呾瀯鞛� Heather Rees鞚� 靹滊獏鞙茧 鞝滌稖霅橃棃鞀惦媹雼�. 鞐赴 鞝滉车霅� 8-K 氤鸽鞐愲姅 靾橃箻順� 鞛 歆�響滉皜 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿�, 靸侅劯頃� 瓴瓣臣鞕� 靹る獏鞚� Exhibit 99.1鞚� 彀胳“頃橃嫮鞁滌槫.
Atossa Therapeutics, Inc. a d茅clar茅 le 12 ao没t 2025 avoir publi茅 un communiqu茅 de presse annon莽ant les r茅sultats financiers du trimestre clos le 30 juin 2025 et fournissant une mise 脿 jour de la soci茅t茅. Le communiqu茅 est joint en tant que Exhibit 99.1 et le d茅p么t comprend un fichier de donn茅es interactif de la page de couverture en tant que Exhibit 104. La Soci茅t茅 indique que les informations figurant aux Items 2.02 et 9.01, y compris l'Exhibit 99.1, ne doivent pas 锚tre consid茅r茅es comme "filed" aux fins de la Section 18 du Exchange Act ni 锚tre soumises 脿 certaines responsabilit茅s pr茅vues par le Securities Act. Ce Current Report est sign茅 par Heather Rees, Chief Financial Officer. Aucune donn茅e financi猫re chiffr茅e ne figure dans le texte de l'8-K pr茅sent茅 ici ; veuillez consulter l'Exhibit 99.1 pour les r茅sultats d茅taill茅s et les commentaires.
Atossa Therapeutics, Inc. berichtete am 12. August 2025, dass eine Pressemitteilung ver枚ffentlicht wurde, die die Finanzergebnisse f眉r das am 30. Juni 2025 endende Quartal ank眉ndigt und ein Unternehmensupdate enth盲lt. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt und die Einreichung enth盲lt eine interaktive Datendatei der Titelseite als Exhibit 104. Das Unternehmen erkl盲rt, dass die Informationen in den Items 2.02 und 9.01, einschlie脽lich Exhibit 99.1, nicht als "filed" im Sinne von Abschnitt 18 des Exchange Act angesehen werden sollen und nicht bestimmten Haftungsbestimmungen des Securities Act unterliegen. Dieser Current Report ist von Heather Rees, Chief Financial Officer, unterzeichnet. Im hier ver枚ffentlichten 8-K-Text sind keine numerischen Finanzkennzahlen enthalten; f眉r detaillierte Ergebnisse und Erl盲uterungen konsultieren Sie bitte Exhibit 99.1.
FAQ
What did Atossa Therapeutics (ATOS) file in this Form 8-K?
Where can I find the Q2 2025 financial results for ATOS referenced in the 8-K?
Is the press release in Exhibit 99.1 considered legally "filed" with the SEC?
Which exhibits were included with this ATOS 8-K?
Who signed the Form 8-K for Atossa Therapeutics?
